2022
DOI: 10.1038/s41598-022-20060-7
|View full text |Cite
|
Sign up to set email alerts
|

Preclinical comparative study of [18F]AlF-PSMA-11 and [18F]PSMA-1007 in varying PSMA expressing tumors

Abstract: A wide variety of 18F-labeled PSMA-targeting PET radiotracers have been developed, including [18F]AlF-PSMA-11. As there is only limited data on the comparison with other 18F-labeled PSMA PET tracers, a comparative preclinical study between [18F]AlF-PSMA-11 and [18F]PSMA-1007 was conducted. Mice with varying PSMA expressing tumors (C4-2, 22Rv1 and PC-3, each n = 5) underwent two PET/CT scans with both [18F]AlF-PSMA-11 and [18F]PSMA-1007. Ten additional mice bearing C4-2 xenografts were subjected to ex vivo biod… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1
1

Relationship

2
0

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 40 publications
0
1
0
Order By: Relevance
“…The most common PET tracer is uorodeoxyglucose (FDG) labelled with uorine-18 ( 18 F) to image glucose metabolism [1]. Other emerging tracers with more speci c uptakes are radiolabeled prostate-speci c membrane antigen (PSMA) [2] or broblast activation protein inhibitor (FAPI) [3] ligands. Preclinical PET imaging serves as a translational tool in tracer development.…”
Section: Introductionmentioning
confidence: 99%
“…The most common PET tracer is uorodeoxyglucose (FDG) labelled with uorine-18 ( 18 F) to image glucose metabolism [1]. Other emerging tracers with more speci c uptakes are radiolabeled prostate-speci c membrane antigen (PSMA) [2] or broblast activation protein inhibitor (FAPI) [3] ligands. Preclinical PET imaging serves as a translational tool in tracer development.…”
Section: Introductionmentioning
confidence: 99%